KPV

The KPV evidence base cited here is 5 sources — 3 preclinical, 1 review. Critically, that evidence is almost entirely preclinical (animal and in-vitro) — no human clinical trials are cited, so efficacy and safety in people remain unproven. Regulatory status: Not FDA-approved.

KPV and BPC-157 are the two most commonly paired peptides for gut and inflammatory applications, and they are frequently stacked together — so a direct comparison is useful. They are complementary: KPV is the inflammation switch, BPC-157 is the repair/angiogenesis agent.

The popular pairing logic: KPV suppresses the inflammatory cascade (NF-κB, pro-inflammatory cytokines) while BPC-157 drives the repair side (angiogenesis, tissue regeneration). Note the WADA difference — BPC-157 is explicitly prohibited, whereas KPV is not named but likely captured by the S0 catch-all.

• KPV is a tripeptide (Lys-Pro-Val, MW ≈ 342.4 g/mol, CAS 67727-97-3) corresponding to the C-terminal positions 11–13 of alpha-melanocyte-stimulating hormone (α-MSH) — it keeps the parent hormone's anti-inflammatory activity but not its pigmentation effects.
• Its primary action is inhibition of NF-κB, a master transcription factor for inflammatory genes, which suppresses pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) at nanomolar concentrations.
• It does NOT bind melanocortin receptors and does not raise cAMP; instead, in the gut it depends on the PepT1 di/tripeptide transporter for cellular uptake — so it is preferentially taken up by inflamed intestinal tissue, where PepT1 is overexpressed.

KPV (Lys-Pro-Val) is a naturally derived tripeptide — the three C-terminal residues of α-MSH, a 13-amino-acid neuropeptide. Despite its tiny size, it retains the potent anti-inflammatory activity of the parent hormone while shedding the pigmentation effects, and it works mainly by shutting down NF-κB signaling, one of inflammation's central control points.

Its most distinctive feature is that it is actively transported into cells by the PepT1 peptide transporter, which is overexpressed in inflamed intestinal tissue. That gives it a degree of natural targeting to diseased gut and makes oral dosing genuinely viable — a rarity among peptides. The strongest evidence is in animal models of inflammatory bowel disease, with additional preclinical signals in dermatitis, airway inflammation, and even antimicrobial activity.

It is not FDA-approved and the evidence base is entirely preclinical. Everything below is research context synthesized from the published literature — not medical guidance, and not instructions for human use.

KPV is the C-terminal tripeptide fragment of α-MSH, made of lysine (K), proline (P), and valine (V). Its molecular formula is C16H30N4O4, molecular weight ≈ 342.43 g/mol, CAS number 67727-97-3.

Its anti-inflammatory story grew out of decades of α-MSH research beginning in the 1980s (notably work by Anna Catania and James Lipton), which showed α-MSH could reduce fever, suppress inflammation, and modulate immune cells well beyond its pigmentation role. Testing progressively smaller fragments identified the C-terminal tripeptide KPV as retaining most — sometimes all — of that anti-inflammatory potency.

This matters for three reasons. KPV's small size makes it far cheaper to synthesize than full-length α-MSH. It does not bind melanocortin receptors or raise intracellular cAMP, so it delivers anti-inflammatory benefit without pigmentary or hormonal effects. And as a tripeptide it can be actively transported across cell membranes by the PepT1 di/tripeptide transporter — a property with major implications for oral bioavailability and targeted delivery to inflamed intestinal tissue.

KPV's anti-inflammatory effect converges on NF-κB, but the route it takes into the cell — especially in the gut — is what makes it pharmacologically distinctive.

There is no FDA-approved dosing for KPV. The ranges below reflect what appears in research literature and community reports, included for research context only — not as instructions for use. Human-equivalent doses have not been formally established, and animal doses do not extrapolate directly.

Reported cycle length clusters around 4–8 weeks, with some using continuous low-dose protocols for chronic inflammation and others cycling off 2–4 weeks. None of this is established by controlled human data.

Responses vary by condition, route, dose, and individual physiology. No controlled human trials have established definitive response curves; the following draws on preclinical data and anecdotal reports.

• Weeks 1–2: possible initial reduction in inflammatory symptoms; some report decreased GI discomfort; mild skin-inflammation improvement.
• Weeks 2–4: more consistent anti-inflammatory effects; continued improvement in gut-related symptoms; visible skin improvement in some.
• Weeks 4–8: where most reported benefit is realized — sustained reduction in inflammatory markers and possible improvement in gut-barrier function.

KPV's evidence is almost entirely preclinical — cell culture and animal models. No large-scale human clinical trials have been completed.

Bottom line: unusually well-characterized at the mechanistic level for a peptide this size, with consistent animal efficacy in IBD — but the complete absence of human trial data is the defining limitation.

KPV is often combined with peptides that address tissue repair, so the inflammatory and regenerative sides are covered together. Research context, not protocol advice.

• KPV + BPC-157 — the most common KPV stack: complementary mechanisms (KPV suppresses NF-κB/cytokines; BPC-157 drives angiogenesis and tissue regeneration), popular for gastrointestinal applications. See the KPV vs. BPC-157 comparison above.
• KPV + TB-500 (Thymosin Beta-4 fragment) — adds cell-migration and anti-fibrotic effects to KPV's anti-inflammatory action.
• KPV + GHK-Cu — pairs collagen/wound-healing support with KPV's inflammation control, explored mainly for skin applications.
• KPV + Thymosin Alpha-1 — for broader immune modulation alongside KPV's targeted anti-inflammatory effect.

KPV usually comes as a lyophilized powder requiring reconstitution before injectable use. The following reflects general laboratory peptide handling only.

• Let the vial reach room temperature; use bacteriostatic water as the vehicle, added slowly down the interior vial wall and swirled gently until dissolved — do not shake vigorously.
• Common ratio: 5 mg KPV + 5 mL bacteriostatic water = 1 mg/mL (100 mcg per 0.1 mL / 10 units on an insulin syringe).
• Lyophilized powder: store at −20°C long-term (stable at room temperature for short periods).
• Reconstituted solution: store at 2–8°C and use within ~4 weeks; protect from light, avoid freeze-thaw, discard if cloudy or particulate.

KPV has a favorable safety profile in preclinical studies — no acute toxicity reported in animal models at therapeutic doses, and it does not appear to broadly suppress immune function the way corticosteroids do. Human safety data, however, does not exist; the following are anecdotal.

A theoretical advantage of KPV's targeted NF-κB mechanism is that, unlike broad immunosuppressants, it does not appear to increase infection risk, thin tissue, or cause corticosteroid-type metabolic effects in animal studies. But long-term human safety data do not exist, and unregulated product carries contamination and batch-variability risks separate from the compound's intrinsic profile — third-party COA verification matters.

KPV is not FDA-approved for any indication and has historically been sold as a research chemical. For a broader overview of where research peptides sit legally, see the peptide legality guide.

• Not FDA-approved for any therapeutic indication; no completed human clinical trials.
• Previously placed on the FDA's Category 2 bulk drug substances list, which restricts compounding.
• In February 2026, HHS Secretary Robert F. Kennedy Jr. announced plans to reclassify ~14 peptides — KPV among them — from Category 2 back to Category 1, which would let licensed compounding pharmacies prepare them with a valid prescription. The formal updated FDA list had not been published as of writing.
• Not DEA-scheduled; possession is not illegal. Available through some clinics and online vendors as a research compound.

Even if reclassified for compounding, KPV would remain an unapproved drug — without standardized dosing, a formal clinical indication, or large-scale Phase III data. Research-grade KPV is for laboratory research only and is not intended for human use.

KPV's WADA status is less clearly defined than BPC-157 (which is explicitly named on the Prohibited List). But WADA's catch-all S0 category prohibits any pharmacological substance with no current approval by a governmental regulatory health authority for human therapeutic use — and because KPV is not approved for human use anywhere, it would likely fall under that blanket prohibition. Tested athletes should treat KPV as prohibited until official guidance says otherwise, and should remember that the risk extends beyond the substance itself to potential contaminants in unregulated product.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.